Buchumschlag

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita -

Weitere Versionen anzeigen (1)

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Lapatinib (L) in combination with capecitabine has been approved for the treatment of HER2+ adva...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bischoff, Joachim (VerfasserIn) , Marmé, Frederik (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 11 October 2016
In: Annals of oncology
Year: 2016, Jahrgang: 27
ISSN:1569-8041
DOI:10.1093/annonc/mdw365.52
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw365.52
Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/273P/2799012
Volltext
Verfasserangaben:J. Bischoff, J. Barinoff, C. Mundhenke, D. Bauerschlag, S.D. Costa, D. Herr, K. Lübe, F. Marmé, N. Maass, G. von Minckwitz, E.-M. Grischke, V. Müller, M. Schmidt, B. Gerber, S. Kümmel, C. Schumacher, P. Krabisch, M. Thill, V. Nekljudova, S. Loibl
Beschreibung
Zusammenfassung:© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Lapatinib (L) in combination with capecitabine has been approved for the treatment of HER2+ advanced breast cancer (ABC) progressed after anthracycline-, taxane-, and trastuzumab (T)-containing therapies. The use is limited by overlapping toxicities. Therefore, other combinations of L with less toxic agents are needed. In the E-VITA study two schedules of Eribulin (E) in association with L have been investigated.Methods: E-VITA (NCT01534455) is a randomized phase II study to determine the efficacy and tolerability of two doses of E plus L in T pre-treated pts with HER2+ ABC. Main eligibility criteria were: ABC not suitable for surgery or radiotherapy alone; adjuvant and up to 3 chemotherapy regimen for ABC. Pts were randomized (1:1) to receive E 1.23mg/m2 iv d1,8 q21 (E1.23)...
Beschreibung:Gesehen am 09.11.2017
Beschreibung:Online Resource
ISSN:1569-8041
DOI:10.1093/annonc/mdw365.52

Ähnliche Einträge